stockportfolio.pro
Ginkgo Bioworks Holdings, Inc. (DNA)
Healthcare · Biotechnology · NYSE
Ginkgo Bioworks Holdings, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $54.18M | $76.66M | $313.84M | $477.71M | $251.46M | $227.04M | $170.16M |
| Gross profit | — | — | — | $273.49M | $197.45M | $182.50M | $123.18M |
| Net income | $-119.33M | $-126.61M | $-1.83B | $-2.10B | $-892.87M | $-547.03M | $-312.76M |
| Net margin | -220.2% | -165.2% | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
Source: Ginkgo Bioworks Holdings, Inc. SEC filings (10-K).
Explore 7 years of Ginkgo Bioworks Holdings, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track DNA in your portfolio →
Ginkgo Bioworks Holdings, Inc. financial history by metric
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Ginkgo Bioworks Holdings, Inc. — frequently asked questions
What is Ginkgo Bioworks Holdings, Inc.'s revenue?
Ginkgo Bioworks Holdings, Inc. (DNA) reported revenue of $170.16M for fiscal year 2025, down 25.1% from the prior year, according to its SEC filings.
Is Ginkgo Bioworks Holdings, Inc. profitable?
No — DNA reported a net loss of $-312.76M in fiscal 2025.
What is DNA's P/E ratio?
Ginkgo Bioworks Holdings, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Ginkgo Bioworks Holdings, Inc. growing?
DNA's revenue grew at roughly 17.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Ginkgo Bioworks Holdings, Inc. have?
As of fiscal year 2025, DNA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Ginkgo Bioworks Holdings, Inc.'s gross margin?
DNA's gross margin was 72.4% in fiscal 2025 — gross profit of $123.18M on revenue of $170.16M.
What is Ginkgo Bioworks Holdings, Inc.'s market cap?
Ginkgo Bioworks Holdings, Inc. (DNA) has a market capitalization of about $506.92M, based on the latest data in our nightly-refreshed cache.
When does Ginkgo Bioworks Holdings, Inc.'s fiscal year end?
DNA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Ginkgo Bioworks Holdings, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.